% | $
Quotes you view appear here for quick access.

Pluristem Therapeutics, Inc. Message Board

mdplanet 1 post  |  Last Activity: Jul 31, 2016 10:59 PM Member since: Jan 25, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by mdplanet Jul 31, 2016 10:59 PM Flag

    Despite the hype allo and aliases attempt to force upon us, the truth remains there is a huge risk involved in this stock. Management is continuously feeding us news of discussions with the FDA, EMA and Japan, but to no avail. We wander along hoping something may happen but nothing is happening. They speak about probabilities and possibilities and discuss forthcoming trials yet to begin.

    How long can we wait? Timelines don't matter much to them as long as they are collecting salaries while stockholders languish waiting for results. Stop the nonsense Zami and follow through for once. Pathetic.

    I dare mention the Phase 2 IC trial which needs 20 more patients to succeed in bringing the desired results management is hoping for. From the May 16, 2016 press release: "Pluristem has expanded the trial to enroll 20 additional patients to be randomized in order to preserve the study’s original design to administer two injections to each of 150 patients. Twenty of the 150 patients originally enrolled did not complete the trial with
    two injections." Why did over 10% of the trial participants drop out? A question that will never be answered. This dang trial is now going on 4 years for sake. SMH.

    Anyway, without rambling, beware the hype.

1.600.00(0.00%)4:00 PMEDT